GJGieira S. Jones

Gieira S. Jones

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gieira S. Jones has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplemental Table S1 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses

    by Zeni Wu, Haydée W.T. Jordão, Gieira S. Jones, Gerry McKenna, Andrea A. Almeida, Dawn Q. Chong, Helen G. Coleman, A. Heather Eliassen, Edward L. Giovannucci, Barry I. Graubard, et al.

    Supplemental Table S1 shows assessment of oral health variables across studies

  • Open Access

    Supplemental Table S3 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses

    by Zeni Wu, Haydée W.T. Jordão, Gieira S. Jones, Gerry McKenna, Andrea A. Almeida, Dawn Q. Chong, Helen G. Coleman, A. Heather Eliassen, Edward L. Giovannucci, Barry I. Graubard, et al.

    Supplemental Table S3 the multivariable hazard ratios and 95% confidence intervals for the association between oral health indicators and risk of liver cancer in the HPFU, NHS and WHI cohorts by smoking status

  • Open Access

    Supplemental Table S2 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses

    by Zeni Wu, Haydée W.T. Jordão, Gieira S. Jones, Gerry McKenna, Andrea A. Almeida, Dawn Q. Chong, Helen G. Coleman, A. Heather Eliassen, Edward L. Giovannucci, Barry I. Graubard, et al.

    Supplemental Table S2 shows the search terms used for the meta-analyses

  • Open Access

    Supplemental Table S4 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses

    by Zeni Wu, Haydée W.T. Jordão, Gieira S. Jones, Gerry McKenna, Andrea A. Almeida, Dawn Q. Chong, Helen G. Coleman, A. Heather Eliassen, Edward L. Giovannucci, Barry I. Graubard, et al.

    Supplemental Table S4 shows the sensitivity analysis for the meta-analysis of periodontal disease and number of missing teeth with liver cancer risk

  • Open Access

    Supplemental Table S5 from Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses

    by Zeni Wu, Haydée W.T. Jordão, Gieira S. Jones, Gerry McKenna, Andrea A. Almeida, Dawn Q. Chong, Helen G. Coleman, A. Heather Eliassen, Edward L. Giovannucci, Barry I. Graubard, et al.

    Supplemental Table S5 shows the sensitivity analysis of the effect of omitting one study at a time from the meta-analysis

  • Oral Health and Risk of Liver Cancer: Evidence from Pooled and Meta-Analyses

    by Zeni Wu, Haydée W.T. Jordão, Gieira S. Jones, Gerry McKenna, Andrea A. Almeida, Dawn Q. Chong, Helen G. Coleman, A. Heather Eliassen, Edward L. Giovannucci, Barry I. Graubard, et al.

    Background: Poor oral health, including periodontal disease and tooth loss, is linked to systemic inflammation and oral microbial dysbiosis, which may promote liver carcinogenesis through the oral–gut–liver axis. However, epidemiologic evidence on oral health and liver cancer risk remains inconsistent. We examined these associations in three prospective US cohorts and conducted a systematic review and meta-analysis of prospective studies. Methods: We pooled data from the Health Professionals Follow-Up Study, Nurses’ Health Study, and Women’s Health Initiative (230,915 participants, 198 liver cancer cases). Oral health, including periodontal disease and tooth loss, was self-reported. Multivariable-adjusted Cox models estimated hazard ratios (HR) and 95% confidence intervals (CI). A systematic review through September 2025 identified four additional prospective studies, which were combined with pooled results in meta-analyses. Results: In the pooled analyses, periodontal disease (HR = 0.99; 95% CI, 0.67–1.47) and complete tooth loss (HR = 1.29; 95% CI, 0.71–2.35) were not associated with liver cancer risk. In the meta-analysis, dominated by one large study, periodontal disease was associated with an increased liver cancer risk (HR = 1.08; 95% CI, 1.03–1.13; n = 4 studies; I2 = 0%). In a linear dose–response meta-analysis, complete tooth loss was associated with an increased risk (HR = 1.32; 95% CI, 1.06–1.66; n = 6; I2 = 0%). Conclusions: The findings of the current investigation suggest that although an association between oral health and liver cancer is possible, the results remain inconclusive. Impact: These findings underscore the need for more studies using harmonized oral health assessments integrating clinical, microbial, and behavioral data to better capture the oral health burden.

  • Open Access

    Discrimination Experiences and All-Cause and Cardiovascular Mortality: Multi-Ethnic Study of Atherosclerosis

    by Wayne R. Lawrence, Gieira S. Jones, Jarrett A. Johnson, Koya P. Ferrell, Jacquita N. Johnson, Meredith S. Shiels, Ana V. Diez Roux, Allana T. Forde

    Background: Epidemiologic studies have documented the associations between experiences of discrimination and adverse health outcomes. However, the relationship between discrimination and mortality, and the factors that may moderate this relationship are not well understood. This study examined whether lifetime and everyday discrimination were associated with all-cause and cardiovascular mortality and whether these associations differed by race and ethnicity, gender, and racial and ethnic residential segregation. Methods: The study included 1633 Black, 1403 Hispanic/Latino, and 2473 White participants aged 45 to 84 years from the Multi-Ethnic Study of Atherosclerosis, enrolled from 2000 to 2002 and followed across 5 exams (2002–2018). Discrimination was measured using the lifetime discrimination (major experiences of unfair treatment) and everyday discrimination (day-to-day experiences of unfair treatment) scales. Racial and ethnic residential segregation was measured using the Gi* statistic. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% CIs, adjusting for sociodemographic characteristics, health behaviors, and clinical risk factors. Results: Each increase in reports of lifetime discrimination was associated with increased all-cause (HR, 1.06 [95% CI, 1.00–1.11]) and cardiovascular (HR, 1.15 [95% CI, 1.04–1.27]) mortality, adjusting for sociodemographic factors, health behaviors, and clinical risk factors. Associations between lifetime discrimination and cardiovascular mortality were observed across all racial and ethnic groups but were strongest and only statistically significant among Black participants (HR, 1.18 [95% CI, 1.02–1.37]). Additionally, in the fully adjusted model, each increase in reports of everyday discrimination was strongly associated with increased cardiovascular mortality (HR, 1.21 [95% CI, 1.03–1.43]). Associations for lifetime and everyday discrimination with all-cause and cardiovascular mortality were not modified by race and ethnicity, gender, or racial and ethnic residential segregation. Conclusions: These findings suggest that experiences of discrimination are associated with increased all-cause and cardiovascular mortality.


  • Prediction of nonalcoholic fatty liver disease using anthropometry and body fat measures by sex and race/ethnicity in the United States

    by Gieira S. Jones, Barry I. Graubard, Christian S. Alvarez, Katherine A. McGlynn

    Objective: The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing in the United States and is strongly linked to obesity in many, but not all, racial/ethnic groups. It is conceivable that the lack of correspondence is related to differential fat distribution. The study objective was to examine which fat distribution measures best predicted NAFLD by sex within racial/ethnic groups.Methods: The analysis included 1,404 participants from the 2017‐2018 National Health and Nutrition Examination Survey (NHANES). Area under the receiver operating characteristic curve (AUC) analyses compared the ability of dual‐energy x‐ray absorptiometry‐measured percentage total fat and abdominal fat with measured BMI, waist circumference, and waist to height ratio to predict ultrasound transient‐elastography‐assessed NAFLD in each sex and racial/ethnic group.Results: AUC analysis found the best predictors of NAFLD among men were waist circumference and total abdominal fat area (AUC: 84.1%) and the best predictor among women was visceral fat (AUC: 85.2). NAFLD prediction by body fat measures, however, was similar between racial/ethnic groups.Conclusions: The best predictors of NAFLD, using body fat distribution measures, vary by sex but not by racial/ethnic group.


  • Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression

    by Gieira S. Jones, Katherine A. Hoadley, Halei Benefield, Linnea T. Olsson, Alina M. Hamilton, Arjun Bhattacharya, Erin L. Kirk, Heather J. Tipaldos, Jodie M. Fleming, Kevin P. Williams, et al.

    Purpose Black women have a 40% increased risk of breast cancer-related mortality. These outcome disparities may reflect differences in tumor pathways and a lack of targetable therapies for specific subtypes that are more common in Black women. Hepatocyte growth factor (HGF) is a targetable pathway that promotes breast cancer tumorigenesis, is associated with basal-like breast cancer, and is differentially expressed by race. This study assessed whether a 38-gene HGF expression signature is associated with recurrence and survival in Black and non-Black women. Methods Study participants included 1957 invasive breast cancer cases from the Carolina Breast Cancer Study. The HGF signature was evaluated in association with recurrence (n = 1251, 171 recurrences), overall, and breast cancer-specific mortality (n = 706, 190/328 breast cancer/overall deaths) using Cox proportional hazard models. Results Women with HGF-positive tumors had higher recurrence rates [HR 1.88, 95% CI (1.19, 2.98)], breast cancer-specific mortality [HR 1.90, 95% CI (1.26, 2.85)], and overall mortality [HR 1.69; 95% CI (1.17, 2.43)]. Among Black women, HGF positivity was significantly associated with higher 5-year rate of recurrence [HR 1.73; 95% CI (1.01, 2.99)], but this association was not significant in non-Black women [HR 1.68; 95% CI (0.72, 3.90)]. Among Black women, HGF-positive tumors had elevated breast cancer-specific mortality [HR 1.80, 95% CI (1.05, 3.09)], which was not significant in non-Black women [HR 1.52; 95% CI (0.78, 2.99)]. Conclusion This multi-gene HGF signature is a poor-prognosis feature for breast cancer and may identify patients who could benefit from HGF-targeted treatments, an unmet need for Black and triple-negative patients.


  • Open Access

    Mammographic breast density and its association with urinary estrogens and the fecal microbiota in postmenopausal women

    by Gieira S. Jones, Heather Spencer Feigelson, Roni T. Falk, Xing Hua, Jacques Ravel, Guoqin Yu, Roberto Flores, Mitchell H. Gail, Jianxin Shi, Xia Xu, et al.

    Breast density, as estimated by mammography, is a strong risk factor for breast cancer in pre- and postmenopausal women, but the determinants of breast density have not yet been established. The aim of this study was to assess if urinary estrogens or gut microbiota alterations are associated with mammographic density in postmenopausal women. Among 54 cancer-free, postmenopausal controls in the Breast and Colon Health study, we classified low- versus high-density women with Breast Imaging Reporting and Data System (BI-RADS, 5th edition) mammographic screening data, then assessed associations with urinary estrogens and estrogen metabolites (determined by liquid chromatography/tandem mass spectrometry), and fecal microbiota alpha and beta diversity (using Illumina sequencing of 16S rRNA amplicons). Multiple logistic regression revealed no significant association between breast density and fecal microbiota metrics (PD_tree P-value = 0.82; un-weighted and weighted UniFrac P = 0.92 and 0.83, respectively, both by MiRKAT). In contrast, total urinary estrogens (and all 15 estrogens/estrogen metabolites) were strongly and inversely associated with breast density (P = 0.01) after adjustment for age and body mass index. Mammographic density was not associated with the gut microbiota, but it was inversely associated with urinary estrogen levels. The finding of an inverse association between urinary estrogens and breast density in cancer-free women adds to the growing breast cancer literature on understanding the relationship between endogenous estrogens and mammographic density.